By my trend analysis, genome sequencing has achieved the steepest cost curve in biotechnology history. From $95 million in 2001 to $200-600 today represents a 99.99% cost reduction—outpacing Moore’s Law by orders of magnitude. This exponential decline hasn’t plateaued; it’s accelerating.
The trajectory is crystal clear: we reach the $10 genome by 2029.
The data supports this prediction. Illumina’s NovaSeq X delivers $200/genome at 20,000 genomes annually. Ultima Genomics claims $100 capability. MGI’s DNBSEQ-T20x2 promises sub-$100 at scale. Competition is driving exponential improvement across three vectors: (1) sequencing chemistry efficiency, (2) computational analysis optimization, and (3) automation reducing labor costs.
The $10 threshold triggers global healthcare transformation. At this price point, whole genome sequencing becomes cheaper than most individual diagnostic tests. Every newborn screening, every cancer diagnosis, every pharmacogenomic decision includes full genomic analysis. We shift from “genome sequencing” as a special procedure to genomic data as standard clinical infrastructure.
Prediction milestones:
- 2026: $75 per genome (improved chemistry + automation)
- 2027: $40 per genome (AI analysis cost reduction)
- 2028: $20 per genome (portable sequencer scaling)
- 2029: $10 per genome (the universal healthcare threshold)
Healthcare system implications: At $10, genome sequencing becomes cost-negative—the pharmacogenomic savings from proper drug selection exceed the test cost. Health systems integrate genomic analysis into routine care.





























